How AI is helping pharma cope with supply chain disruption

As the Covid-19 crisis continues to unsettle global economies and business sectors worldwide, pharma companies are facing huge disruption to their supply chains and clinical research.

And while research into potential Covid-19 vaccines and treatments is speeding along, the pandemic has slowed or brought to a halt clinical trials for other diseases, with organisations like Eli Lilly and other big name pharma’s’ putting the brakes on non Covid-19 trial activity. In fact, 50% of respondents in a recent BSI survey said they will be making changes to their supply chain moving forward.

In this climate, with pharmaceutical supply chains under so much pressure, businesses are understandably focused on protecting supplier relationships as different parties are forced to cancel agreements, delay their contractual obligations or renegotiate key terms.